Cover Image
市場調查報告書

癌症免疫療法的藥物開發與免疫檢查點藥:開發平台的最新資訊

Targeting Immune Checkpoints in Cancer Immunotherapy Drug Pipeline Update

出版商 BioSeeker Group AB 商品編碼 317979
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症免疫療法的藥物開發與免疫檢查點藥:開發平台的最新資訊 Targeting Immune Checkpoints in Cancer Immunotherapy Drug Pipeline Update
出版日期: 2016年08月04日 內容資訊: 英文
簡介

免疫檢查點抑制劑目前有Yervoy (ipilimumab)、Keytruda (Pembrolizumab)、Opdivo (nivolumab)等三種認証核可藥。Bristol-Myers Squibb的Yervoy(CTLA4標的抗體)在2011年首次通過認証成為針對無法切除或轉移性黑色素瘤患者用藥劑。2013年全球銷售額Yervoy單體就寫下將近10億(9億6,000萬)美金的記錄。隔年2014年繼小野藥品工業的Opdivo,Merck & Co的Keytruda也新獲得認証。Keytruda及Opdivo都是PD-1抑制劑,通過認証為黑色素瘤的治療藥。雖然以癌症免疫檢查點為標的的藥劑開發計劃不少,但業界同時也締結許多與併用療法相關的契約。目前在309件開發計劃下有59個業者及其合作夥伴企業正在開發109種免疫檢查點藥劑。

本報告提供免疫檢查點藥最新開發趨勢的相關調查,為您彙整開發經營者,標的,開發階段,適應症,生物結構,作用機制等詳細內容。

開發經營者

藥物名及別名

  • 商標名
  • 學名藥
  • 代碼名稱

開發階段

  • 已上市
  • 登記前
  • 第三階段
  • 第二階段
  • 第一階段
  • 前臨床
  • 中斷
  • 中止

適應症

標的

突然變異

  • COSMIC (Catalogue Of Somatic Mutations In Cancer)

生物結構

標的表現圖譜

途徑參照

  • BioCarta
  • KEGG
  • NCI-Nature
  • NetPath

機制

化合物

藥物簡介

  • 主要經營者和合作夥伴經營者
  • 標的及標的分子功能
  • 標的部位
  • 突然變異
  • 生物結構
  • 標的途徑
  • 作用機制
  • 開發計劃
  • 藥物說明
  • 化合物資料
  • 專利資料
  • 第四階段資料
  • 第三階段資料
  • 第二階段資料
  • 第一階段資料
  • 第0相資料
  • 臨床前資料
  • 藥物研發資料

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BSG18518

BioSeeker's Targeting Immune Checkpoints in Cancer Immunotherapy: Drug Pipeline Update is the most up to date and comprehensive pipeline review and competitive assessment you can get on this hot and fast moving area in cancer immunology. There are two sides of immune checkpoint control; those which activate and those which inhibit T-cell activation. BioSeeker's Targeting Immune Checkpoints in Cancer Immunotherapy: Drug Pipeline Update covers both sides extensively.

There are currently four approved immune check point inhibitors, namely Yervoy (ipilimumab), Opdivo (nivolumab), Keytruda (pembrolizumab) and Tecentriq (atezolizumab). Bristol-Myers Squibb's Yervoy, a CTLA4 targeting antibody, was first to be approved in 2011 for the treatment of patients with unresectable or metastatic melanoma. In 2014 came two more approvals, Opdivo was first approved in Japan through Ono Pharmaceutical and later followed by Merck & Co's Keytruda. Both Keytruda and Opdivo are PD-1 inhibitors and were first approved for treatment of melanoma. In 2016 Roche's PD-L1 inhibitor Tecentriq was granted an accelerated approval by the US FDA for the treatment of people with locally advanced or metastatic urothelial carcinoma. Collectively, immune checkpoint inhibitors are currently approved for the treatment of five different cancer types: bladder cancer, Hodkin's lymphoma, melanoma, non-small cell lung cancer and renal cancer. The world-wide Q2 2016 sales for these drugs were; Yervoy (241m USD), Opdivo (840m USD), Keytruda (314m USD) and Tecentriq (19m CHF).

There are today 120 companies plus partners developing 227 immune checkpoints drugs in 835 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 19 drugs. Targeting Immune Checkpoints In Cancer Immunotherapy Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 71 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 66 out of the 66 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 23 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use?

  • Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive drug intelligence operations * Excellent starting point for world wide benchmarking * Compare portfolio and therapy focus with your peers * Speed up pro-active in-/out licensing strategy work * Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug. Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.

Table of Contents

Drug Pipeline Update at a Glance

Investigators

  • Includes more than 120 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
  • Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.

Drug name & Synonyms

  • Lists commercial, generic and code names for drugs.

Developmental stage

  • This Drug Pipeline Update contains 227 immune checkpoints drugs in development, which have a total of 835 developmental projects in cancer. In addition there are suspended and ceased drugs.
  • Pipeline Breakdown According to Number of Drugs
  • Marketed# 4
  • Pre-registration# 2
  • Phase III# 11
  • Phase II# 36
  • Phase I# 86
  • Preclinical# 103
  • No Data# 1
  • Suspended# 4
  • Ceased# 19
  • Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.

Indications

  • Included immune checkpoints drugs are also in development for 131 other indications, where of 115 are different cancer indications.
  • Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.

Targets

  • Mutations
  • All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 66 out of the 66 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
  • Biological Structures
  • The identity of available biological structures on 50 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 407 structures available today among drug targets.
  • Identified drugs are linked to more than 71 different targets, divided into 23 classifications of molecular function:
  • Antigen binding
  • Carboxypeptidase activity
  • Catalytic activity
  • Cell adhesion molecule activity
  • Cysteine-type peptidase activity
  • Cytokine activity
  • Defense/immunity protein activity
  • G-protein coupled receptor activity
  • Growth factor activity
  • Heat shock protein activity
  • Molecular function unknown
  • Oxidoreductase activity
  • Receptor activity
  • Receptor binding
  • Receptor signaling complex scaffold activity
  • RNA-directed DNA polymerase activity
  • Serine-type peptidase activity
  • Structural constituent of cytoskeleton
  • T cell receptor activity
  • T cell receptor binding
  • Transcription regulator activity
  • Transmembrane receptor activity
  • Transmembrane receptor protein tyrosine kinase activity
  • Sub-Cellular Localization
  • Identified targets are categorized into 14 different primary and alternate sub-cellular localizations:
  • Cell surface
  • Clathrin-coated vesicle
  • Cytoplasm
  • Endoplasmic reticulum
  • Endosome
  • Extracellular
  • Golgi apparatus
  • Kinetochore
  • Lysosome
  • Mitochondrion
  • Nucleolus
  • Nucleus
  • Plasma membrane
  • Vesicle
  • Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.

Target Expression Profile

  • Direct links are provided from inside the application to 85 protein expression profiles of 55 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
  • 48 different normal tissue types
  • 20 different types of cancer
  • 47 cell lines
  • 12 samples of primary blood cells

Pathway Referals

  • Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.
  • BioCarta# 77 Pathways
  • KEGG# 103 Pathways
  • NCI-Nature# 81 Pathways
  • NetPath# 19 Pathways
  • Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.

Mechanism

  • In total there are different drug mechanism of action represented in this Drug Pipeline Update.
  • Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.

Compound

  • Identified drug compounds are described by:
  • Compound type, Chemical name, CAS Number and molecular weight
  • Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.

Drug Profile

  • Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:
  • Drug Name & Synonyms
  • Presentation of drug name and synonyms

Principal Company & Partners

  • Presentation of principal company and partners

Target and Molecular Function of Target

  • Described target(s) is/are presented with:
  • Official Gene Symbol - Chromosome Location - Gene & Protein Name - Molecular Function

Target Localization

  • Described target(s) is/are presented with primary and alternate localizations.
  • Target Expression Profiles
  • Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
  • 48 different normal tissue types
  • 20 different types of cancer
  • 47 cell lines
  • 12 samples of primary blood cells

Mutation

  • All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.
  • Biological Structures
  • The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.

Targeted Pathways

  • Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.

Mechanism

  • Drug mechanism of action

Developmental Projects

  • Summary field of developmental projects for the drug, including indication, developmental stage and status.
  • Example:
  • Cancer, myeloma - Phase II Clinical Trial - Active
  • Cancer, prostate - Phase III Clinical Trial - Ceased

Drug Description

  • Short introduction to drug

Compound Data

  • Compound type, Chemical name, CAS Number and molecular weight

Patent Data

  • Available patent information related to the drug is presented here.

Fillings and Approvals

  • Approvals and submissions
  • Analyst comments
  • Deals & Licensing
  • Collaborations and deals
  • Availability for licensing

Phase IV Data

  • Available Phase IV development data, developmental history and scientific data.

Phase III Data

  • Available Phase III development data, developmental history and scientific data.

Phase II Data

  • Available Phase II development data, developmental history and scientific data.

Phase I Data

  • Available Phase I development data, developmental history and scientific data.

Phase 0 Data

  • Available Phase 0 development data, developmental history and scientific data.

Preclinical Data

  • Available preclinical development data, developmental history and scientific data.

Discovery Data

  • Available discovery development data, developmental history and scientific data.

Application Features

  • Search, Find and Filter Panel with Initial Result Presentation
  • With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.
  • The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.
  • Direct linkage from inside the application to related internet resources
  • Drug data is linked to search engines like Google and PubMed
  • Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.
  • Direct links to company web pages of companies

Dynamic Report Generator

  • Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.

System Requirements

  • Operating system: Windows (2000/XP/Vista/7/8) for Mac Users the service is only available online
  • Browser Application (Internet Explorer, Firefox, Chrome, Safari)
  • Internet access (to access related internet resources)
Back to Top